Quick Answer
BIOMARIN PHARMACEUTICAL INC reported Operating Income Loss of $409.48 million for the year ending 2025.
- BIOMARIN PHARMACEUTICAL INC showed a decrease of -15.4% in Operating Income Loss from 2024 to 2025.
- This data is from BIOMARIN PHARMACEUTICAL INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $3.04 million | Q3 2010: -$1.94 million | Q1 2011: $2.29 million | Q2 2011: $768.0 thousand | Q3 2011: -$15.52 million | Q1 2012: -$21.87 million | Q2 2012: -$30.95 million | Q3 2012: -$10.49 million | Q1 2013: -$32.92 million | Q2 2013: -$20.05 million | Q3 2013: -$50.72 million | Q1 2014: -$26.46 million | Q2 2014: -$18.88 million | Q3 2014: $11.20 million | Q1 2015: -$65.86 million | Q2 2015: -$64.29 million | Q3 2015: -$81.87 million | Q1 2016: -$80.92 million | Q2 2016: -$572.81 million | Q3 2016: -$60.09 million | Q1 2017: -$20.21 million | Q2 2017: -$38.81 million | Q3 2017: -$13.73 million | Q1 2018: -$44.37 million | Q2 2018: -$25.26 million | Q3 2018: -$15.74 million | Q1 2019: -$53.95 million | Q2 2019: -$41.35 million | Q3 2019: $4.01 million | Q1 2020: $104.96 million | Q2 2020: -$40.95 million | Q3 2020: -$55.94 million | Q1 2021: $25.09 million | Q2 2021: $11.67 million | Q3 2021: -$53.22 million | Q1 2022: $137.33 million | Q2 2022: $39.15 million | Q3 2022: -$2.42 million | Q1 2023: $62.40 million | Q2 2023: $65.57 million | Q3 2023: $30.53 million | Q1 2024: $88.46 million | Q2 2024: $120.45 million | Q3 2024: $113.89 million | Q1 2025: $223.89 million | Q2 2025: $276.89 million | Q3 2025: -$46.69 million.
- Over the full 18 years of available data (2008 to 2025), BIOMARIN PHARMACEUTICAL INC's Operating Income Loss has grown by 930.0%.
- Historical annual values: Fiscal year 2025: $409.48 million | Fiscal year 2024: $484.21 million | Fiscal year 2023: $185.77 million | Fiscal year 2022: $160.97 million | Fiscal year 2021: -$82.34 million | Fiscal year 2020: -$43.44 million | Fiscal year 2019: -$100.46 million | Fiscal year 2018: -$123.52 million | Fiscal year 2017: -$14.70 million | Fiscal year 2016: -$803.43 million | Fiscal year 2015: -$110.70 million | Fiscal year 2014: -$92.89 million | Fiscal year 2013: -$156.01 million | Fiscal year 2012: -$110.22 million | Fiscal year 2011: -$33.89 million | Fiscal year 2010: $544.0 thousand | Fiscal year 2009: $16.43 million | Fiscal year 2008: $39.76 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: